$ALDX
Aldeyra Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023058829 Filed on November 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.800M $2.590M
YoY Change -62.0% -20.18%
% of Gross Profit
Research & Development $4.298M $6.962M
YoY Change -52.04% -39.67%
% of Gross Profit
Depreciation & Amortization $66.47K $70.00K
YoY Change -0.27% 7.18%
% of Gross Profit
Operating Expenses $6.098M $6.962M
YoY Change -55.48% -39.67%
Operating Profit -$9.550M
YoY Change -35.4%
Interest Expense $1.345M $538.7K
YoY Change 69.24% 29.22%
% of Operating Profit
Other Income/Expense, Net $1.363M
YoY Change 489.43%
Pretax Income -$4.753M -$8.190M
YoY Change -63.16% -43.72%
Income Tax
% Of Pretax Income
Net Earnings -$4.753M -$8.187M
YoY Change -63.16% -43.75%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14
Diluted Earnings Per Share -$0.08 -$0.14
COMMON SHARES
Basic Shares Outstanding 58.82M 58.60M
Diluted Shares Outstanding 58.99M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $142.8M $143.3M
YoY Change -18.06% -22.66%
Cash & Equivalents $14.31M $143.3M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $4.987M $0.00
YoY Change 53.83% -100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $147.8M $147.2M
YoY Change -18.35% -22.31%
LONG-TERM ASSETS
Property, Plant & Equipment $516.6K $7.774K
YoY Change 2579.5% -70.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $516.6K $72.23K
YoY Change 92.36% -65.37%
TOTAL ASSETS
Total Short-Term Assets $147.8M $147.2M
Total Long-Term Assets $516.6K $72.23K
Total Assets $148.3M $147.3M
YoY Change -18.18% -22.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.338M $247.2K
YoY Change 901.35% -81.09%
Accrued Expenses $5.776M $7.843M
YoY Change -58.94% -23.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $15.15M $13.46M
YoY Change 1561.24% 8.13%
Total Short-Term Liabilities $22.26M $21.62M
YoY Change 44.92% -10.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $2.657M
YoY Change -100.0% -19.55%
Other Long-Term Liabilities $6.272M
YoY Change
Total Long-Term Liabilities $6.272M $2.657M
YoY Change -57.97% -19.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.26M $21.62M
Total Long-Term Liabilities $6.272M $2.657M
Total Liabilities $28.53M $24.27M
YoY Change -5.78% -11.72%
SHAREHOLDERS EQUITY
Retained Earnings -$394.3M -$389.5M
YoY Change 10.52% 13.29%
Common Stock $514.1M $512.5M
YoY Change 1.23% 1.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $119.8M $123.0M
YoY Change
Total Liabilities & Shareholders Equity $148.3M $147.3M
YoY Change -18.18% -22.36%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$4.753M -$8.187M
YoY Change -63.16% -43.75%
Depreciation, Depletion And Amortization $66.47K $70.00K
YoY Change -0.27% 7.18%
Cash From Operating Activities $500.4K -$8.030M
YoY Change -104.46% -36.14%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.012M -320.0K
YoY Change -126.74%
NET CHANGE
Cash From Operating Activities 500.4K -8.030M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities -1.012M -320.0K
Net Change In Cash -511.9K -8.350M
YoY Change -103.25% -209.31%
FREE CASH FLOW
Cash From Operating Activities $500.4K -$8.030M
Capital Expenditures $0.00 $0.00
Free Cash Flow $500.4K -$8.030M
YoY Change -104.46% -36.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001341235
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36332
dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1968197
dei Entity Address Address Line1
EntityAddressAddressLine1
131 Hartwell Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 320
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
761-4904
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ALDX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58822083
CY2023Q3 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
143334888
CY2022Q4 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
144419364
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
29881520
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3875126
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6722229
CY2023Q3 us-gaap Assets Current
AssetsCurrent
147210014
CY2022Q4 us-gaap Assets Current
AssetsCurrent
181023113
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
64459
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
249265
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7774
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19279
CY2023Q3 us-gaap Assets
Assets
147282247
CY2022Q4 us-gaap Assets
Assets
181291657
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
247194
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
133625
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7843389
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14065885
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
13461108
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
911763
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
65628
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
249265
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
21617319
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15360538
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2657189
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14923090
CY2023Q3 us-gaap Liabilities
Liabilities
24274508
CY2022Q4 us-gaap Liabilities
Liabilities
30283628
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59187326
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59187326
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58560078
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58560078
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
59187
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
58560
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
512454738
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
507770045
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-103938
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-389506186
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-356716638
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
123007739
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
151008029
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
147282247
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
181291657
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6961669
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11539620
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25160437
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38344594
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2588701
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3244936
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11535868
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10638602
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9550370
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14784556
us-gaap Operating Income Loss
OperatingIncomeLoss
-36696305
us-gaap Operating Income Loss
OperatingIncomeLoss
-48983196
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1902242
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
648242
us-gaap Investment Income Interest
InvestmentIncomeInterest
5463928
us-gaap Investment Income Interest
InvestmentIncomeInterest
1094001
CY2023Q3 us-gaap Interest Expense
InterestExpense
538743
CY2022Q3 us-gaap Interest Expense
InterestExpense
416917
us-gaap Interest Expense
InterestExpense
1557171
us-gaap Interest Expense
InterestExpense
1233279
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1363499
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
231325
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3906757
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-139278
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8186871
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-14553231
us-gaap Net Income Loss
NetIncomeLoss
-32789548
us-gaap Net Income Loss
NetIncomeLoss
-49122474
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58990189
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58990189
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58457863
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58457863
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58858631
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58858631
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58352991
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58352991
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8186871
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-14553231
us-gaap Net Income Loss
NetIncomeLoss
-32789548
us-gaap Net Income Loss
NetIncomeLoss
-49122474
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
30
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
103938
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-285733
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
30
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
103938
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-285733
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8186871
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14553201
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32685610
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49408207
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
151008029
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4943228
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
163941
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
111102
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
532951
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
103938
aldx Net Loss
NetLoss
-32789548
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
123007739
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
205735523
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4646241
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1123427
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
96665
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-285733
aldx Net Loss
NetLoss
-49122474
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
162193649
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
129883199
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1627170
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
158648
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
58544
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
532951
CY2023Q3 aldx Net Loss
NetLoss
-8186871
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
123007739
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
174029008
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1521074
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1123427
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
73341
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
30
CY2022Q3 aldx Net Loss
NetLoss
-14553231
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
162193649
us-gaap Profit Loss
ProfitLoss
-32789548
us-gaap Profit Loss
ProfitLoss
-49122474
us-gaap Share Based Compensation
ShareBasedCompensation
6553112
us-gaap Share Based Compensation
ShareBasedCompensation
5467684
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
283444
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
248397
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
14542
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
26380
us-gaap Depreciation
Depreciation
196311
us-gaap Depreciation
Depreciation
192064
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2847103
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1191940
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
113569
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
287224
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8016017
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1260585
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30826568
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45406010
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16317
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
92938213
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
36000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56954530
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
163941
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1123427
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
532951
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
111102
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
96665
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-257908
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1220092
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1084476
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-101140448
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
144419364
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229790989
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143334888
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128650541
us-gaap Interest Paid Net
InterestPaidNet
1262354
us-gaap Interest Paid Net
InterestPaidNet
981833
us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NATURE OF BUSINESS </span></div></div><p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries (the “Company” or “Aldeyra”), a Delaware corporation, is a clinical-stage biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s principal activities to date include research and development activities along with related general business planning, including raising capital.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company’s management evaluates its estimates and assumptions on an ongoing basis. Management’s most significant estimates in the Company’s condensed consolidated financial statements include, but are not limited to, clinical trial accruals, deferred and accrued research and development costs, stock-based compensation, and accounting for income taxes and related valuation allowance. Although these estimates and</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assumptions </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span>
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7200692
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7200692
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6588585
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6588585
CY2023Q3 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29985458
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
103938
CY2022Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
29881520
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
144419364
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
29881520
CY2023Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2023Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
3056972
CY2022Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
2605252
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
605967
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
432230
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
0
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3242026
CY2023Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
212187
CY2022Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
442721
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3875126
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6722229
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5240956
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3821904
CY2023Q3 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1972031
CY2022Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
8476422
CY2023Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
630402
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
1767559
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7843389
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14065885
CY2023Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2023Q3 aldx End Of Term Charge
EndOfTermCharge
1156194
CY2022Q4 aldx End Of Term Charge
EndOfTermCharge
911763
CY2023Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
37897
CY2022Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
76910
CY2023Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
13461108
CY2022Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
911763
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2657189
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14923090
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1042500
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
15292500
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
16335000
aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2020 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
CY2022 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1600000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
789217
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2236771
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6553112
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5467684
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5403982
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.9
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M21D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10506953
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1172775
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.96
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
297703
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4802
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
99833
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.56
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6174419
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.37
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M26D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7529935
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4281954
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.31
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M29D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5791281
CY2023Q3 us-gaap Share Price
SharePrice
6.68
aldx Common Stock Withheld For Tax Obligations On Option Exercise
CommonStockWithheldForTaxObligationsOnOptionExercise
-73807
aldx Share Based Payment Arrangement Stock Withholding Valued
ShareBasedPaymentArrangementStockWithholdingValued
500000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
64500
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y3M
us-gaap Operating Lease Expense
OperatingLeaseExpense
196400
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
66626
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
998
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
65628
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
65628
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
65628
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
66626
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
66626
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2023Q3 aldx Indemnification Obligations Claims Outstanding
IndemnificationObligationsClaimsOutstanding
0
CY2023Q3 aldx Cash Reserve For Indemnities And Guarantees
CashReserveForIndemnitiesAndGuarantees
0

Files In Submission

Name View Source Status
aldx-20230930_def.xml Edgar Link unprocessable
0000950170-23-058829-index-headers.html Edgar Link pending
0000950170-23-058829-index.html Edgar Link pending
0000950170-23-058829.txt Edgar Link pending
0000950170-23-058829-xbrl.zip Edgar Link pending
aldx-20230930.htm Edgar Link pending
aldx-20230930.xsd Edgar Link pending
aldx-ex31_1.htm Edgar Link pending
aldx-ex31_2.htm Edgar Link pending
aldx-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img129967027_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
aldx-20230930_lab.xml Edgar Link unprocessable
aldx-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aldx-20230930_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
aldx-20230930_cal.xml Edgar Link unprocessable